Tirzepatide is a GIP and GLP-1 receptor agonist that increases fullness, slows stomach emptying and helps control blood sugar.
What Tirzepatide does and why that matters
Tirzepatide copies two natural hormone signals, GIP and GLP-1. It helps the body release insulin when blood sugar is high, reduces glucagon, slows food leaving the stomach and lowers appetite. In everyday terms, many patients feel full with less food, which can improve blood-sugar control and support weight loss. The approved use and instructions depend on the exact Mounjaro or Zepbound product. [1,2]
Function evidence: Known action described in approved product labels
What patients may notice
Many patients notice that they become full with less food or stay satisfied for longer, which can make sustained weight loss more achievable. In diabetes treatment, tirzepatide can also improve blood-sugar control. The direct SURMOUNT-5 trial gives a clearer comparison than placing separate trials side by side: average weight loss at 72 weeks was 20.2% with tirzepatide and 13.7% with semaglutide in adults with obesity who did not have diabetes. Individual results and tolerability vary, and Mounjaro and Zepbound retain product-specific indications and instructions. [1,2,3]
What supports this description: Approved-product evidence and a direct randomized obesity comparison
Tirzepatide Dosing status
Dose: Zepbound is product specific; the label starts at 2.5 mg weekly and identifies 5 mg, 10 mg, or 15 mg maintenance doses for weight management. [2] | Frequency: Follow the exact product label and prescription. | Cycle: Prescription treatment duration is individualized; do not invent a cycle. | Route: Product and presentation specific.
Preparation: Do not apply a generic vial recipe. Follow the instructions for the exact dispensed presentation..
Tirzepatide is the active ingredient in the FDA-approved products Mounjaro and Zepbound. SURMOUNT-5 directly compared maximum tolerated doses in adults with obesity who did not have diabetes. Average weight loss at 72 weeks was 20.2% with tirzepatide and 13.7% with semaglutide. The older 22.5% and 15% figures came from separate trials and should not be used as a head-to-head comparison. [1,2]
Tirzepatide Effects
Head-to-head weight result. In SURMOUNT-5, mean weight decreased by 20.2% with tirzepatide and 13.7% with semaglutide at 72 weeks. The trial included 751 adults with obesity who did not have diabetes. [1]
Tirzepatide Side Effects
Approved-label safety. Zepbound and Mounjaro labels contain boxed and other warnings, contraindications, adverse reactions, and product-specific administration instructions. Use the exact current label and prescriber plan. [2]
Compounded-product differences. Compounded tirzepatide is not FDA-approved and is not automatically interchangeable with Zepbound or Mounjaro. Concentration, container, excipients, testing, instructions, and legal basis can differ. [3]
Frequently Asked Questions About Tirzepatide
What did the direct tirzepatide-versus-semaglutide trial find?
In SURMOUNT-5, mean weight decreased by 20.2% with tirzepatide and 13.7% with semaglutide at 72 weeks. [1]
What is the approved Zepbound dosing framework?
The label starts Zepbound at 2.5 mg once weekly for 4 weeks. Later increases are 2.5 mg after at least 4 weeks. For weight management, the listed maintenance doses are 5 mg, 10 mg or 15 mg. These instructions are for Zepbound under prescriber supervision, not an unspecified vial. [2]
Evidence
FDA-approved medicines with direct comparative trial evidence. Tirzepatide is the active ingredient in the FDA-approved products Mounjaro and Zepbound. SURMOUNT-5 directly compared maximum tolerated doses in adults with obesity who did not have diabetes. Average weight loss at 72 weeks was 20.2% with tirzepatide and 13.7% with semaglutide. The older 22.5% and 15% figures came from separate trials and should not be used as a head-to-head comparison. [1,2]
Approval status: FDA-approved only for the named products and labeled uses. [1,2,3]
References
Jastreboff AM, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity N Engl J Med, 2025. PMID 40353578
U.S. Food and Drug Administration Zepbound prescribing information , . Source
U.S. Food and Drug Administration FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss , 2026. Source
Storage
Exact dispensed product: Follow its current label and pharmacy instructions. Do not infer stability from another formulation or from the CDC multidose-vial convention.
Educational evidence summary. Approval applies only to the named product and indication; compounded, investigational, and research-market products are different categories.
◇An FDA-approved label or a patient-specific prescription from a licensed pharmacy
◇The active ingredient, strength, dosage form, concentration, lot, and dispensing instructions
◇Identity or purity tests only support the tests performed; they do not prove sterility, endotoxin safety, dose accuracy, stability, or clinical suitability
◇A “research use only” vial is not a patient medicine
